Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Feb 13;169(3):523–530. doi: 10.1007/s10549-018-4696-z

Table 3.

Relationship of HER2 status and [89Zr]trastuzumab-PET/CT results (per-patient basis) using SUVmax cutoff point of 3.2.

Type Proportion (95% Exact Binomial Confidence Interval)
Sensitivity 75.8% (57.7%, 88.9%)
Specificity 61.5% (31.6%, 86.1%)
Positive Predictive Value 83.3% (65.3%, 94.4%)
Negative Predictive Value 50.0% (24.7%, 75.3%)